Method and system for prognosis and treatment of diseases using portfolio of genes

Patent metadata

Field	Value
Publication number	US-10011876-B2
Application number	US-201113988764-A
Country	US
Kind code	B2
Filing date	Jun 21, 2011
Priority date	Nov 23, 2010
Publication date	Jul 3, 2018
Grant date	Jul 3, 2018

Abstract

This disclosure generally relates to a method, a system and a kit for diagnosing and treating various disease conditions using the gene expression value in a given sample obtained from a subject. This disclosure further relates to selecting the right set of genes as a portfolio of genes for a particular disease. Providing a set of appropriate portfolio of gene for studying the gene expression values and using the values as a diagnostic tool is also disclosed. The gene expression value is further used for intervention by pharmaceuticals as a prediction model for the treatment of the disease. An individual may have a personalized health card that may store the gene expression value for that particular individual. A system may store the data for portability and integrated view of the individual's medical data for effective diagnosis and treatment.

First claim

What is claimed is:

1. A method comprising:
isolating a sample from a subject suffering from a disease to measure gene expression values for a portfolio of genes;
measuring the gene expression values for the portfolio of genes based on determining an amount of RNA produced by each gene that can code for one of: a protein and a peptide;
analyzing, through a processor, the gene expression values for the portfolio of genes within said sample through repeatedly applying at least one of: penalized discriminant analyses and recursive feature elimination, said portfolio of genes being one of: a set of SEQ ID NO. 22 to SEQ ID NO. 43 and a combination of SEQ ID NOs thereof;
obtaining, through the processor, a gene expression value profile of the portfolio of genes for the sample from the subject based on the analysis of the gene expression values, the gene expression value profile comprising a statistically significant number of genes that vary in expression value from an expression value of the same genes in at least one of: a normal and a disease control sample; and
normalizing, through the processor, a gene expression level of the portfolio of genes using a house keeping gene, the at least one of: the normal and the disease control sample and the sample from the subject in addition to obtaining the gene expression value profile, the house keeping gene being GAPDH.

2. The method of claim 1 , further comprising:
performing a statistical analysis on the gene expression level for the portfolio of genes, a statistically significant value associated therewith representing collectively a level of gene expression values for the portfolio of genes that indicates that said subject has at least one of: a cancer, a progression of the cancer, an effect of treatment for the cancer and a location of the cancer.

3. The method of claim 1 , wherein the disease is breast cancer.

4. The method of claim 1 , wherein the sample is at least one of: a biopsy sample, a fine needle aspirate, parafilm embedded samples, a tumor tissue, immune cells, whole blood, saliva, urine, synovial fluid, bone marrow, cerebrospinal fluid, vaginal mucus, cervical mucus, nasal secretions, sputum, semen, amniotic fluid, bronchoalveolar lavage fluid, and other cellular exudates from a patient having cancer.

5. A method of diagnosing cancer, comprising:
analyzing, through a processor, gene expression values for a portfolio of genes within a sample from a subject through repeatedly applying at least one of: penalized discriminant analyses and recursive feature elimination, said portfolio of genes being one of: a set of SEQ ID NO. 22 to SEQ ID NO. 43 and a combination of SEQ ID NOs thereof;
obtaining, through the processor, a gene expression value profile of the portfolio of genes for the sample from the subject based on the analysis of the gene expression values, the gene expression value profile comprising a statistically significant number of genes that vary in expression value from an expression value of the same genes in at least one of: a normal and a control sample;
normalizing, through the processor, a gene expression level of the portfolio of genes using a house keeping gene, the at least one of: the normal and the control sample and the sample from the subject in addition to obtaining the gene expression value profile, the house keeping gene being GAPDH; and
identifying differential modulation of each gene relative to the expression of the same genes in the at least one of: the normal and the control sample in the portfolio of genes in accordance with the analysis related to the obtained gene expression value profile and the normalized gene expression level, the differential modulation of the each gene indicating activation thereof to one of: a higher level and a lower level in the sample of the subject relative to expression thereof in the at least one of: the normal and the control sample.

6. The method of claim 5 , wherein the cancer to be diagnosed is breast cancer.

7. The method of claim 5 , wherein the sample from the subject is breast tissue, and the method further comprises:
creating a report summarizing data obtained by the analysis of the gene expression values.

Assignees

• Kandula Mahesh
• Krisani Biosciences Pvt Ltd

Inventors

• Kandula Mahesh

Classifications

• C12Q2600/106

  Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism · CPC title

• C12Q2600/158

  Expression markers · CPC title

• C12Q1/6886 Primary

  for cancer (immunoassay for cancer G01N33/575) · CPC title